乳腺癌蒽环类新辅助化疗疗效与ER、PR、HER2表达的关系(3)
 |
| 第1页 |
参见附件。
[4] Fishher ER, Wang J, Bryant J, et al. Pathobioloqy of preoperative chemotherapy: findings form the National Surgical Adjuvant Breast and Bowel(NSABP)B-18. Cancer,2002, 95(4):681-695.
[5] 王坤,李学瑞,周清,等.乳腺癌之华山论剑.循证医学，2005,5(1):45-55.
[5] Wang Kun, Li Xuerui, Zhou Qing, et al. The debate of breast cancer. Evidence-Based Medicine，2005,5(1):45-55.
[6] Burcombe RJ,Makrie A, Richman PI,et al. Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.Br J Cancer,2005,92(1):147-155.
[7] Ogston KN,Miller ID,Schofield AC,et al. Can patients likelihood of benefiting from primary chemotherapy for breast ancer be predicted before commencement of treatment.Breast Vancer Res Treat,2004，86:181-189.
[8] Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer, 1999, 35: 574-579.
[9] Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage Ⅱand Ⅲ breast cancer efficacy and correiation with biojogical markers in a phase Ⅱ,maiticenter study. Clin Cancer Res,2005, 9(2): 686-692.
[10] Penault-Llorca F, Cavre A, Bouchet Mishellany F, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.Int J Oncol,2003,22(6): 1319-1325.
[11] Gregory RK, Powle TJ, Salter J, et al. Prognostic relevance of cerbB-2 expression following neoadjuvant chemotherapy in patients in a randomized trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat,2006, 59 (2): 171-175.
[12] Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer,2007, 97(7): 1758-1765.
(收稿日期：2011-08-01)
(本文编辑：车艳)
您现在查看是摘要介绍页，详见PDF附件。